(Q38001798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

An overview of the mTOR pathway as a target in cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Jessica K Altman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Leonidas C Platanias

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

12 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

481-489

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR, translation initiation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Phosphatidic acid-mediated mitogenic activation of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Phospholipase D confers rapamycin resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR signaling in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR signaling: implications for cancer and anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Targeting mTOR for the treatment of AML. New agents and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Insulin increases the association of Akt-2 with Glut4-containing vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Activation of mTORC2 by association with the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

The role of LKB1 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Targeting the mTOR signaling network in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

New molecular targets in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Molecular pathways: BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Mechanisms of resistance to BCR-ABL kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Renal-cell carcinoma--molecular pathways and therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

mTOR inhibitors in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Future directions in renal cell carcinoma: 2011 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Mechanisms of sarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677439

10.1517/14728222.2012.677439

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22494490%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference